Zurich, Switzerland, October 19, 2026 – DKSH has signed an agreement to acquire 100% of NewBridge Pharmaceuticals (“NewBridge” or the “Company”), a Dubai-headquartered healthcare commercialization platform with operations across 14 markets in the MENA region, for an enterprise value of USD 390 million. The acquisition represents a pivotal step in expanding DKSH Healthcare’s footprint beyond Asia Pacific and advances DKSH Healthcare’s strategic roadmap to become a leading multi-regional, end-to-end outsourcing platform. It also aligns with DKSH’s strategy to accelerate M&A. It enhances DKSH’s offering as a single partner of choice for biopharmaceutical companies across a wider range of geographies and strengthens the commercialization of innovative medicines for specialty and rare diseases, including launch excellence, market access and medical affairs.
